Want to join the conversation?
$LRCX 4Q15 Call: Operating expenses in the June quarter grew a little bit to $355MM but decreased as a percentage of revenue to 24%, which was down from 25% in the March quarter. In the quarter 63% OpEx spend went to R&D which was about the same level as last quarter.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.